Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting.

Front Pharmacol · 2021 · PMC8724779 · PMID 34992535

Europe PMC DOI

hedged sentences

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significancep = 0.15not close (p > 0.1)

Comparing with linagliptin, empagliflozin reduced AKI risk in both male and female patients, but it did not reach statistical significance in the female subgroup (aHR, 0.68, p = 0.15).

also in 111,027 other papers

showed a trendp = 0.15not close (p > 0.1)

Moreover, older patients showed a trend of less, yet insignificant, AKI events among new users of empagliflozin compared with that of linagliptin (aHR, 0.70, p = 0.15).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.